Cosmos Holdings Inc. - COSM STOCK NEWS

Cosmos Health (NASDAQ:COSM) has secured a distribution agreement with Virax Biolabs for Avian Influenza Virus (AIV) Real-Time PCR Kits. The agreement grants exclusive distribution rights in Greece and Cyprus, along with non-exclusive rights in 12 European countries and 2 GCC nations (Oman and Bahrain).

The RT-PCR tests detect RNA from AIV, including H5, H7, and H9 subtypes, particularly the H5N1 strain. These kits enable healthcare professionals to quickly identify infections in individuals exposed to infected livestock or high-risk environments. Under the agreement, Cosmos Health will handle import, sales, and distribution, while Virax will manage regulatory compliance and documentation for product approvals.

The partnership aims to enhance global preparedness against avian influenza outbreaks by providing specialized testing capabilities that can differentiate between various strains, supporting rapid response and intervention in healthcare systems.

Cosmos Health (NASDAQ:COSM) has appointed Professor Dimitrios Trafalis, MD, as Head of Oncology at its Research and Development division. Professor Trafalis, currently serving at the National and Kapodistrian University of Athens, brings expertise in oncology-hematology, cancer cytogenetics, and personalized cancer therapies. He will lead research initiatives focusing on preclinical and clinical development strategies, regulatory support, and cutting-edge oncology studies.

As a specialist in biosciences, cancer research, and drug development, Professor Trafalis has authored multiple scientific publications and received numerous citations and international research grants. In his new role, he will oversee preclinical and clinical protocols while presenting key developments at global medical conferences and in scientific journals.

Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas and CFO George Terzis have increased their stake in the company by approximately 343,122 common shares, valued at $200,000. Mr. Siokas acquired 257,334 shares worth $150,000, while Mr. Terzis purchased 85,778 shares valued at $50,000.

The CEO expressed disappointment in the current share price, which he believes is below the company's intrinsic value, but views it as an opportunity for increased investment. He highlighted the company's assets, including growing proprietary brands, a pharmaceutical GMP license for contract manufacturing, and an R&D team working on cancer and obesity treatments.

Taglich Brothers has released an updated research report on Cosmos Health (NASDAQ:COSM), maintaining a Speculative Buy rating with a $3 price target. The report projects 25% revenue growth to $68.4 million in FY 2025, up from an estimated $54.7 million in FY 2024. The company expects significant improvements in financial metrics, including gross margin expansion to 19.4% and positive EPS of $0.01 in 2025. Growth drivers include Cana Laboratories investments, projected to generate over $10 million in annual gross profit at full capacity, and expanded distribution agreements across Europe and Middle East. The company's stock currently trades at 0.2x sales, below the sector average of 2.1x.

Cosmos Health (NASDAQ:COSM) has announced the integration of Bitcoin and Ethereum as part of its treasury reserve assets. This strategic move aligns with the company's investment in new technologies, following their recent acquisition of Cloudscreen, an AI-driven drug repurposing platform. The company aims to diversify its balance sheet through cryptocurrency and blockchain-related assets, anticipating potential upside as these digital assets gain wider adoption. Additionally, Cosmos Health plans to accept cryptocurrency payments from customers.

Cosmos Health (NASDAQ:COSM) reported Q3 2024 results showing a 3.22% revenue decrease to $12.41 million, while maintaining stable gross profit at $1.21 million. The company achieved significant cost reductions with operating expenses down 18.6% to $3.45 million. Net loss improved by 34.8% to $2.18 million compared to Q3 2023. The balance sheet strengthened with total assets up 6% to $64.52 million and cash position reaching $3.31 million. CosmoFarm achieved record revenue of approximately $43 million in the first ten months of 2024, while Amazon UK sales of proprietary brands surged by 160%.

Cosmos Health (NASDAQ:COSM) reports significant growth and transformation in its latest shareholder letter. The company achieved revenue increases of 18.1% in Q1 2024 and 6.8% in Q2 2024 year-over-year. From 2018 to June 2024, total assets grew 194% to $60.83 million, while total debt decreased 71% to $3.95 million. The company's updated 2024-2027 guidance projects revenue growth to $155.80 million and net income reaching $20.44 million by 2027. Key developments include strategic acquisitions, R&D initiatives, international brand expansion, and a strong balance sheet with stockholders' equity at $32.1 million as of Q2 2024.

Cosmos Health's subsidiary CosmoFarm reported record revenue of $43 million for the first ten months of 2024, marking an 8.62% increase from the previous year, accompanied by a 21% rise in gross profit. The growth is attributed to investments in advanced robotic systems for automated operations, expanded sales and marketing initiatives, and strategic acquisitions of distribution networks. CosmoFarm, operating from a 29,000-square-foot facility in Athens, serves over 1,500 pharmacies and is projected to exceed $52 million in annualized revenue.

Cosmos Health Inc. (NASDAQ:COSM) has reported a significant 160% increase in sales of its proprietary brands on Amazon UK for the year-to-date 2024. Sales have risen to $596,000 from $230,000 during the same period in 2023. The company's CEO, Greg Siokas, expressed satisfaction with the strong reception of their brands in the UK market and anticipates continued growth momentum. He also highlighted that the company's brands benefit from strong profit margins, which is expected to contribute to solid profitability as they expand their revenue base.